2021 is shaping up to be another banner year for biotech companies. According to BioSpace, funds appear to be in near-endless supply as companies advance next-gen technologies and therapeutics for the health of all. BioSpace reviews a few raking in cash for their programs.
Amryt inked an all-stock acquisition deal with Chiasma. The combined company will focus on rare and orphan diseases with three marketed products and a strong development pipeline.
Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca has been on their Covid-19 vaccine efforts, and here is a look at what else is going on with these companies.
France’s Servier bolstered its presence in oncology with the acquisition of the clinical and research-stage oncology business of Agios Pharmaceuticals in a deal worth up to $2 billion.
AstraZeneca is acquiring Alexion Pharmaceuticals for $39 billion, with the deal expected to close in the third quarter of 2021.
If all things go well, the Pfizer-BioNTech Covid-19 vaccine will receive EUA from the U.S. Food and Drug Administration around December 10 or within a few days after, and the Moderna vaccine will receive EUA around December 17 or within a few days after.
Urovant Sciences and Genmab reported disappointing clinical trial announcements.
BioSpace reviewed the third-quarter 2020 financial announcements from some of the biopharma industry’s leading players.
Shares of CStone Pharmaceuticals were up after Pfizer invested $200 million into the company for a nearly 10% stake to support the development of a checkpoint inhibitor aimed at the oncology market in China.
Sanofi announced the acquisition of Principia Biopharma in a deal valued at about $3.68 billion as the French company continues to transform its R&D division to more heavily emphasize oncology and other lucrative programs.